Charcot neuro-osteoarthropathy has traditionally been described as a rare but devastating complication of diabetes.
As we recently discussed in “An Enigma Wrapped in Edema: Rethinking Charcot Arthropathy”—and in the accompanying International Wound Journal manuscript—the condition remains under-recognized, underdiagnosed, and undertreated.
The word “rare,” however, can lull health systems into complacency.
A newly published regional registry study in Diabetes Care delivers a much-needed wake-up call. Charcot is not simply a disorder of bones and joints. It appears to be a flashing red signal of whole-person vulnerability.
The foot may be the smoke alarm. The fire is systemic.
A rare diagnosis with remarkably common catastrophe
Milbourn and colleagues examined linked health care data from 127,513 adults with diabetes within NHS Greater Glasgow and Clyde, Scotland, between 2015 and 2024. They identified 140 people with a first recorded diagnosis of Charcot neuro-osteoarthropathy. The mean age was 59 years, and 67% were men.1
During a median follow-up of 4.6 years:
- 87.9% experienced at least one emergency hospital admission
- 31.4% underwent a minor or major lower-extremity amputation
- 37.9% died
- Estimated five-year survival was 67%
- Estimated five-year amputation-free survival was only 44%
Put another way, fewer than half of these patients were both alive and free from amputation five years after diagnosis.
The median amputation-free survival was just over four years.
The apparent rarity of Charcot must also be interpreted cautiously. As earlier nationwide studies from Sweden and Denmark suggest, the epidemiology is more substantial—and more nuanced—than the traditional “zebra diagnosis” framing implies.
Charcot is a systemic risk phenotype
The study’s most important contribution may not be any single percentage. It is the pattern created when these outcomes are viewed together.
Charcot appears to identify a person whose reserves are already dangerously depleted.
Advanced chronic kidney disease was associated with worse outcomes across the board. A high-risk or active foot classification was associated with an eightfold greater risk of amputation. Older age was independently associated with mortality.1
These findings should change how we respond to a new Charcot diagnosis.
The traditional clinical question has been:
“How do we stabilize this foot?”
The more appropriate question may be:
“What is happening to this person—and how quickly can we stabilize the entire system?”
The prognosis is consistently sobering
This is not the first study to identify Charcot as a marker of serious long-term risk.
A previous meta-analysis of amputation and mortality following diabetic Charcot arthropathy found substantial rates of both outcomes across the available literature.
Several years ago, our group also reported a pooled five-year mortality of approximately 29% among people with Charcot neuroarthropathy. As discussed in “Five-Year Mortality and Direct Costs of Care for People With Diabetic Foot Complications Are Comparable to Cancer”, Charcot belongs within a spectrum of diabetic foot complications carrying survival implications comparable to many cancers.2
The new Scottish registry arrives in essentially the same sobering neighborhood, with estimated five-year mortality of approximately one-third.
This is no longer an isolated signal from one database or one health system. Different populations and different methods continue to point in the same direction.
Charcot is associated with a prognosis comparable to many serious systemic diseases. Yet it is still frequently treated as an orthopedic curiosity, a casting problem, or a particularly dramatic radiograph.
That framing is too narrow.
Our friends and colleagues have previously called for a paradigm shift in how Charcot neuroarthropathy is understood and treated. The new data extend that argument beyond foot reconstruction and deformity prevention: Charcot should trigger a systemic-risk response.
What should happen after diagnosis?
A new Charcot diagnosis should activate a coordinated pathway—not merely an appointment for another cast.
That pathway should include:
- Immediate protection and effective offloading
- Rapid access to an interdisciplinary limb-preservation team
- Assessment for ulceration, infection, deformity, and vascular disease
- Renal and cardiovascular risk review
- Medication and glycemic assessment
- Evaluation of mobility, falls, frailty, and social support
- Continued surveillance after the acute Charcot episode has entered remission
Remission must not become discharge.
The transition from an active, hot, and swollen foot to a cooler and more stable foot does not erase the patient’s systemic risk. The visible fire may have quieted, but the building remains vulnerable.
What the study cannot tell us
This was a regional observational study involving only 140 identified Charcot cases. Diagnoses depended on routinely collected health records, and Charcot is notoriously underrecognized and miscoded.
The study also cannot establish that Charcot itself caused the hospitalizations, amputations, or deaths. Charcot may instead be a marker for the accumulated burden of neuropathy, kidney disease, vascular disease, inflammation, impaired mobility, and social vulnerability.
But from a clinical perspective, that distinction does not weaken the signal.
A smoke alarm does not cause the fire. Its value is that it tells us where—and when—to act.
The goal: more hospital-free, activity-rich, and limb-intact days
Success in Charcot care cannot be defined solely by radiographic consolidation or a reduction in skin temperature.
We should also be measuring whether the person remains alive, ambulatory, out of the hospital, and free from amputation.
This study should move Charcot neuro-osteoarthropathy out of its clinical silo. It belongs within the broader framework of chronic disease management, cardiovascular and renal risk reduction, mobility preservation, and coordinated multidisciplinary care.
The same lesson is emerging across the spectrum of diabetic foot disease. As we recently wrote, a foot ulcer is a whole-body diagnosis. The new data suggest that Charcot neuro-osteoarthropathy should be regarded in much the same way.
When Charcot appears, the foot is telling us something about the whole person.
We should listen.
References
- Milbourn VEL, Barn R, Tieges Z, et al. Emergency Hospitalization, Amputation, and Survival After Charcot Neuro-Osteoarthropathy Diagnosis in People With Diabetes: A Regional Registry-Based Cohort Study. Diabetes Care. Published online July 28, 2026. doi:10.2337/dc26-0373.
- Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula WV, Bus SA. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res. 2020;13:16. doi:10.1186/s13047-020-00383-2.
#CharcotFoot #CharcotNeuroOsteoarthropathy #DiabeticFoot #LimbPreservation #AmputationPrevention #ActAgainstAmputation #ToeAndFlow #DiabetesCare
Leave a Reply